165 related articles for article (PubMed ID: 31099559)
1. Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.
Zhang X; Dong G; Li H; Chen W; Li J; Feng C; Gu Z; Zhu F; Zhang R; Li M; Tang W; Liu H; Xu Y
J Med Chem; 2019 Jun; 62(11):5579-5593. PubMed ID: 31099559
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment.
Zhang R; Li H; Zhang X; Li J; Su H; Lu Q; Dong G; Dou H; Fan C; Gu Z; Mu Q; Tang W; Xu Y; Liu H
Eur J Med Chem; 2021 Feb; 211():113004. PubMed ID: 33218684
[TBL] [Abstract][Full Text] [Related]
3. Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
Song G; Zhu X; Li J; Hu D; Zhao D; Liao Y; Lin J; Zhang LH; Cui ZN
Bioorg Med Chem; 2017 Oct; 25(20):5709-5717. PubMed ID: 28888661
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
Song G; Zhao D; Hu D; Li Y; Jin H; Cui Z
Bioorg Med Chem Lett; 2015 Oct; 25(20):4610-4. PubMed ID: 26320621
[TBL] [Abstract][Full Text] [Related]
5. Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis.
Song Z; Huang YY; Hou KQ; Liu L; Zhou F; Huang Y; Wan G; Luo HB; Xiong XF
J Med Chem; 2022 Mar; 65(5):4238-4254. PubMed ID: 35188767
[TBL] [Abstract][Full Text] [Related]
6. Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).
Cameron RT; Coleman RG; Day JP; Yalla KC; Houslay MD; Adams DR; Shoichet BK; Baillie GS
Biochem Pharmacol; 2013 May; 85(9):1297-305. PubMed ID: 23473803
[TBL] [Abstract][Full Text] [Related]
7. Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
Gewald R; Grunwald C; Egerland U
Bioorg Med Chem Lett; 2013 Aug; 23(15):4308-14. PubMed ID: 23806553
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design and structure-activity relationships of 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.
Liao Y; Guo Y; Li S; Wang L; Tang Y; Li T; Chen W; Zhong G; Song G
Bioorg Med Chem Lett; 2018 Apr; 28(7):1188-1193. PubMed ID: 29545101
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases.
Carzaniga L; Amari G; Rizzi A; Capaldi C; De Fanti R; Ghidini E; Villetti G; Carnini C; Moretto N; Facchinetti F; Caruso P; Marchini G; Battipaglia L; Patacchini R; Cenacchi V; Volta R; Amadei F; Pappani A; Capacchi S; Bagnacani V; Delcanale M; Puccini P; Catinella S; Civelli M; Armani E
J Med Chem; 2017 Dec; 60(24):10026-10046. PubMed ID: 29200281
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.
Dong C; Virtucio C; Zemska O; Baltazar G; Zhou Y; Baia D; Jones-Iatauro S; Sexton H; Martin S; Dee J; Mak Y; Meewan M; Rock F; Akama T; Jarnagin K
J Pharmacol Exp Ther; 2016 Sep; 358(3):413-22. PubMed ID: 27353073
[TBL] [Abstract][Full Text] [Related]
11. Discovery of oral and inhaled PDE4 inhibitors.
Ting PC; Lee JF; Kuang R; Cao J; Gu D; Huang Y; Liu Z; Aslanian RG; Feng KI; Prelusky D; Lamca J; House A; Phillips JE; Wang P; Wu P; Lundell D; Chapman RW; Celly CS
Bioorg Med Chem Lett; 2013 Oct; 23(20):5528-32. PubMed ID: 24018187
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of 4,5,6,7-tetrahydro-1H-1,2-diazepin-7-one derivatives as a new series of Phosphodiesterase 4 (PDE4) inhibitors.
Guariento S; Karawajczyk A; Bull JA; Marchini G; Bielska M; Iwanowa X; Bruno O; Fossa P; Giordanetto F
Bioorg Med Chem Lett; 2017 Jan; 27(1):24-29. PubMed ID: 27890378
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.
Taltavull J; Serrat J; Gràcia J; Gavaldà A; Córdoba M; Calama E; Montero JL; Andrés M; Miralpeix M; Vilella D; Hernández B; Beleta J; Ryder H; Pagès L
Eur J Med Chem; 2011 Oct; 46(10):4946-56. PubMed ID: 21871695
[TBL] [Abstract][Full Text] [Related]
14. Identification of a PDE4-Specific Pocket for the Design of Selective Inhibitors.
Feng X; Wang H; Ye M; Xu XT; Xu Y; Yang W; Zhang HT; Song G; Ke H
Biochemistry; 2018 Jul; 57(30):4518-4525. PubMed ID: 29975048
[TBL] [Abstract][Full Text] [Related]
15. PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes.
Jin J; Mazzacuva F; Crocetti L; Giovannoni MP; Cilibrizzi A
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511275
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel inhibitors of phosphodiesterase 4 with 1-phenyl-3,4-dihydroisoquinoline scaffold: Structure-based drug design and fragment identification.
Liao Y; Jia X; Tang Y; Li S; Zang Y; Wang L; Cui ZN; Song G
Bioorg Med Chem Lett; 2019 Nov; 29(22):126720. PubMed ID: 31610942
[TBL] [Abstract][Full Text] [Related]
17. Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.
Liang J; Huang YY; Zhou Q; Gao Y; Li Z; Wu D; Yu S; Guo L; Chen Z; Huang L; Liang SH; He X; Wu R; Luo HB
J Med Chem; 2020 Mar; 63(6):3370-3380. PubMed ID: 32115956
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3438-42. PubMed ID: 23582272
[TBL] [Abstract][Full Text] [Related]
19. Advances in the Development of Phosphodiesterase-4 Inhibitors.
Peng T; Qi B; He J; Ke H; Shi J
J Med Chem; 2020 Oct; 63(19):10594-10617. PubMed ID: 32255344
[TBL] [Abstract][Full Text] [Related]
20. Identification of 2,3-disubstituted pyridines as potent, orally active PDE4 inhibitors.
Kato Y; Kawasaki M; Nigo T; Nakamura S; Fusano A; Teranishi Y; Ito MN; Sumiyoshi T
Bioorg Med Chem; 2013 Sep; 21(18):5851-4. PubMed ID: 23910988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
